Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Ofatumumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alvotech, Advanz Pharma Extend Partnership for 3 More Biosimilars
    Alvotech, Advanz Pharma Extend Partnership for 3 More Biosimilars

    28 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/28/3089259/0/en/Alvotech-and-Advanz-Pharma-Extend-Strategic-Partnership-to-Commercialize-Three-Additional-Biosimilars-in-Europe.html

    GLOBENEWSWIRE
    28 May 2025
    Share Share
    Novartis to present new data at AAN on Kesimpta® safety in MS.
    Novartis to present new data at AAN on Kesimpta® safety in MS.

    25 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/25/3048413/0/en/Novartis-to-present-new-data-at-AAN-including-seven-year-disability-outcomes-and-safety-analysis-of-Kesimpta-in-people-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    25 Mar 2025
    Share Share
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.
    Novartis' Arzerra (ofatumumab) Receives Suppl Approval in the U.S.

    12 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125326

    FDA
    12 Apr 2024
    Share Share
    Novartis presents new five-year data disability outcomes and safety of Kesimpta
    Novartis presents new five-year data disability outcomes and safety of Kesimpta

    20 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/20/2650654/0/en/Novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-Kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    20 Apr 2023
    Share Share
    Novartis presents new 5-year data on disability outcomes and safety of Kesimpta
    Novartis presents new 5-year data on disability outcomes and safety of Kesimpta

    19 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novartis-presents-new-five-year-data-on-disability-outcomes-and-safety-of-kesimpta-ofatumumab-in-people-living-with-relapsing-multiple-sclerosis-301802531.html

    PR NEWSWIRE
    19 Apr 2023
    Share Share